These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 33764257)

  • 1. Gene Expression Analysis of Pediatric Acute Myeloid Leukemia Identified a Hyperactive ASXL1/BAP1 Axis Linked with Poor Prognosis and over Expressed Epigenetic Modifiers.
    Elyamany G; Akhter A; Kamran H; Rizwan H; Shabani-Rad MT; Alkhayat N; Al Sharif O; Elborai Y; Al Shahrani M; Mansoor A
    Pediatr Hematol Oncol; 2021 Sep; 38(6):581-592. PubMed ID: 33764257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-derived neomorphic mutations in ASXL1 impairs the BAP1-ASXL1-FOXK1/K2 transcription network.
    Xia YK; Zeng YR; Zhang ML; Liu P; Liu F; Zhang H; He CX; Sun YP; Zhang JY; Zhang C; Song L; Ding C; Tang YJ; Yang Z; Yang C; Wang P; Guan KL; Xiong Y; Ye D
    Protein Cell; 2021 Jul; 12(7):557-577. PubMed ID: 32683582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis.
    Asada S; Goyama S; Inoue D; Shikata S; Takeda R; Fukushima T; Yonezawa T; Fujino T; Hayashi Y; Kawabata KC; Fukuyama T; Tanaka Y; Yokoyama A; Yamazaki S; Kozuka-Hata H; Oyama M; Kojima S; Kawazu M; Mano H; Kitamura T
    Nat Commun; 2018 Jul; 9(1):2733. PubMed ID: 30013160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia.
    Wang L; Birch NW; Zhao Z; Nestler CM; Kazmer A; Shilati A; Blake A; Ozark PA; Rendleman EJ; Zha D; Ryan CA; Morgan MAJ; Shilatifard A
    Nat Cancer; 2021 May; 2(5):515-526. PubMed ID: 35122023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms.
    Asada S; Kitamura T
    Int J Hematol; 2019 Aug; 110(2):179-186. PubMed ID: 30515738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics and prognostic study of adult acute myeloid leukemia patients with
    Lin Y; Wang Y; Zheng Y; Wang Z; Wang Y; Wang S
    Hematology; 2020 Dec; 25(1):446-456. PubMed ID: 33250015
    [No Abstract]   [Full Text] [Related]  

  • 7. [Using next generation sequencing technology to analyze gene mutations in patients with acute myeloid leukemia and the impact on prognosis].
    Zhao CX; Wang JM; Li JM; Zou SH; Chen FY; Liang AB; Hou J; Hu XX; Zhang YX; Gu SY; Zhu JY; Li P; Du J; Yang YN; Qin YW; Wang XR; Wang C
    Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(40):3145-3151. PubMed ID: 31694105
    [No Abstract]   [Full Text] [Related]  

  • 8. ASXL2 mutations are frequently found in pediatric AML patients with t(8;21)/ RUNX1-RUNX1T1 and associated with a better prognosis.
    Yamato G; Shiba N; Yoshida K; Shiraishi Y; Hara Y; Ohki K; Okubo J; Okuno H; Chiba K; Tanaka H; Kinoshita A; Moritake H; Kiyokawa N; Tomizawa D; Park MJ; Sotomatsu M; Taga T; Adachi S; Tawa A; Horibe K; Arakawa H; Miyano S; Ogawa S; Hayashi Y
    Genes Chromosomes Cancer; 2017 May; 56(5):382-393. PubMed ID: 28063196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics and prognosis analysis of patients with de novo ASXL1-mutated AML treated with the C-HUNAN-AML-15 protocol: A multicenter study by the South China Pediatric AML Collaborative Group.
    Zeng M; Chen K; Tian X; Zou R; Feng X; Li C; Li J; Zheng M; Mai H; Yang L; He Y; Xu H; Wen H; He X
    Cancer Med; 2023 Jun; 12(12):13182-13192. PubMed ID: 37132266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.
    Hou HA; Tien HF
    Expert Rev Hematol; 2016 May; 9(5):447-69. PubMed ID: 26789100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing hyperactivated BAP1 attenuates mutant ASXL1-driven myeloid malignancies in human haematopoietic cells.
    Bai J; Chen Z; Chen C; Zhang M; Zhang Y; Song J; Yuan J; Jiang X; Xing W; Yang J; Bai J; Zhou Y
    Cancer Lett; 2021 Oct; 519():78-90. PubMed ID: 34186160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic hematopoietic stem cell transplantation could improve the survival of acute myeloid leukemia patients with ASXL1 mutations.
    Zhou L; An J; Hou C; Ding Z; Qiu H; Tang X; Sun A; Chen S; Xu Y; Liu T; Wu D
    Hematology; 2021 Dec; 26(1):340-347. PubMed ID: 33840380
    [No Abstract]   [Full Text] [Related]  

  • 13. [Molecular mechanisms by which the mutant ASXL1/BAP1 complex aggravates myeloid leukemia].
    Asada S
    Rinsho Ketsueki; 2020; 61(4):392-405. PubMed ID: 32378586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ASXL1 mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts.
    Valletta S; Dolatshad H; Bartenstein M; Yip BH; Bello E; Gordon S; Yu Y; Shaw J; Roy S; Scifo L; Schuh A; Pellagatti A; Fulga TA; Verma A; Boultwood J
    Oncotarget; 2015 Dec; 6(42):44061-71. PubMed ID: 26623729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic characteristics and prognostic significance of co-mutated ASXL1/SRSF2 acute myeloid leukemia.
    Richardson DR; Swoboda DM; Moore DT; Johnson SM; Chan O; Galeotti J; Esparza S; Hussaini MO; Van Deventer H; Foster MC; Coombs CC; Montgomery ND; Sallman DA; Zeidner JF
    Am J Hematol; 2021 Apr; 96(4):462-470. PubMed ID: 33502020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
    Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
    Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of BAP1 function leads to EZH2-dependent transformation.
    LaFave LM; Béguelin W; Koche R; Teater M; Spitzer B; Chramiec A; Papalexi E; Keller MD; Hricik T; Konstantinoff K; Micol JB; Durham B; Knutson SK; Campbell JE; Blum G; Shi X; Doud EH; Krivtsov AV; Chung YR; Khodos I; de Stanchina E; Ouerfelli O; Adusumilli PS; Thomas PM; Kelleher NL; Luo M; Keilhack H; Abdel-Wahab O; Melnick A; Armstrong SA; Levine RL
    Nat Med; 2015 Nov; 21(11):1344-9. PubMed ID: 26437366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia.
    Di Giacomo D; La Starza R; Gorello P; Pellanera F; Kalender Atak Z; De Keersmaecker K; Pierini V; Harrison CJ; Arniani S; Moretti M; Testoni N; De Santis G; Roti G; Matteucci C; Bassan R; Vandenberghe P; Aerts S; Cools J; Bornhauser B; Bourquin JP; Piazza R; Mecucci C
    Blood; 2021 Sep; 138(9):773-784. PubMed ID: 33876209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype.
    Prats-Martín C; Burillo-Sanz S; Morales-Camacho RM; Pérez-López O; Suito M; Vargas MT; Caballero-Velázquez T; Carrillo-Cruz E; González J; Bernal R; Pérez-Simón JA
    Cancer Med; 2020 Jun; 9(11):3637-3646. PubMed ID: 32216059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex.
    Balasubramani A; Larjo A; Bassein JA; Chang X; Hastie RB; Togher SM; Lähdesmäki H; Rao A
    Nat Commun; 2015 Jun; 6():7307. PubMed ID: 26095772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.